Dual-purpose CAR-T cells demonstrated similar cytotoxic activity against CD19/HER2+ tumor cells regardless of PD-L1, but enhanced cytokine release and improved proliferative capacity were only observed in the presence of both CD19/HER2 and PD-L1. The gene discussed is ERBB2; the disease is neoplasm.